| 摘要 |
<p>The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R<1>, R<2>, R<3>, and R<4> are each independently H, N02, CF3, SCF3, CN, halo, OH, OR<6>, NH2, NHR<6>, NR<6>R<7>, N<+>R<6>R<7>R<8>, COOH, COOR<6>, CONH2, CONHR<6>, CONR<6>R<7>, COH, COR<E>, SR', SOR<E>, S02R<6>, SO2OH, SO2OR<6>, S02NH2, S02NHR<6>, S02NR<6>R<7>, alkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl, with the proviso that at least one of R<1>, R<2>, R<3>, and R<4> is other than H; or R<1> and R<2>, R<2> and R<3>, or R<3> and R<4>, may together form part of a fused or unfused saturated or unsaturated ring system, optionally containing up to two heteroatoms selected from N, 0, and S; R<5> is OH, OR<9>, CN, CONH2, CONHNH2, CONHOH, CONHR<9>, CONR<9>R<10>, NH2, NHR<9>, or NR<9>R<10>; each R<6>, R<7> and R<8> is independently hydrocarbyl, or two of R<6>, R<7> and R<8> together form part of a saturated or unsaturated ring system, optionally containing up to two heteroatoms selected from N, 0, and S; each R<9> and R<10 >is independently hydrocarbyl, or R<9> and R<10 >together form part of a saturated or unsaturated ring system, optionally containing up to two heteroatoms selected from N, 0, and S; in the preparation of a medicament for treating a proliferative disorder.</p> |
